nemu

  1. Home
  2. Corporate Information
  3. Profile and History

Profile and History

Corporate Profile

Company name AskAt Inc.
Locations Head Office
2F Dai-Tokai Bldg., 3-22-8
Meieki, Nakamura-ku, Nagoya, Aichi 450-002, Japan
Establishment January 7, 2013
Capital 282,091,000 yen
Board of Directors Akihiro Furuta         
Representative Director, President

Shinichi Koizumi      
Director, Vice-President, Chief Scientific Officer

Andrew M Saidel     
External Director

Masami Nakane      
External Director, Audit and Supervisory                              Committee

Hironari Hatsuzawa 
External Director, Audit and Supervisory                              Committee

Daisuke Nishii         
External Director, Audit and Supervisory                              Committee
Operating Team Tatsuya Asai           
Director, Administration

History

January 2013 Is launched with capital of 1,000,000 yen as a wholly owned subsidiary of RaQualia Inc.
Acquires the following compounds as intellectual property:
・EP4 antagonist / AAT-007, AAT-008
・5-HT4 partial agonist / AAT-009
・COX-2 inhibitor / AAT-076
President Shinichi Koizumi
June 2013 Acquires management rights from RaQualia Inc.
September 2014 Relocation of head office to Showa-ku, Nagoya
March 2015 Akihiro Furuta becomes president
Becomes fully independent of RaQualia
June 2015 Issues new shares to third parties (capital 9,750,000 yen)
August 2015 Issues new shares to third parties (capital 17,000,000 yen)
November 2015 Acquires CB2 agonist intellectual property from RaQualia Inc.
Issues new shares to third parties (capital 32,000,000 yen)
January 2016 Concludes license agreement with RMX (Haihe) for AAT-076 and AAT-007 in China.
Issues new shares to third parties (capital 37,000,000 yen)
March 2016 Issues new shares to third parties (capital 62,000,000 yen)
December 2016 Concludes license agreement with Ningbo Tai Kang for AAT-007 in China.
January 2017 Aratana Therapeutics (subsidiary of Elanco Animal Health) launches Galliprant® in USA for Canine Osteoarthritis-associated Pain
May 2017 Issues new shares to third parties (capital 87,000,000 yen)
December 2017 Concludes worldwide license agreement (excluding China and Taiwan) with Arrys Therapeutics (subsidiary of Ikena Oncology) for AAT-007 and AAT-008
Transition to a company with board of directors / company auditor
February 2018 Concludes worldwide license agreement with Aratana Therapeutics (subsidiary of Elanco Animal Health) for AAT-008 in animal health
March 2018 Transition to a company with audit and supervisory committee
August 2018 Relocation of head office to Nakamura-ku, Nagoya
September 2018 RMX(Haihe) initiates Clinical Study of EP4 Antagonist of AAT-007 in the People's Republic of China
October 2018 Arrys Therapeutivs (currently Ikena Oncology), initiates CRC Clinical Study with AAT-007 and Pembrolizumab
December 2018 Arrys Therapeutivs (currently Ikena Oncology), initiates Phase 1b/2 Clinical Studies of AAT-007 in Collaboration with Merck
April 2019 Elanco Animal Health launches Galliprant® in EU for Canine Osteoarthritis-associated Pain
June 2019 Ningbo NewBay Medical Technology Co., Ltd. initiates Clinical Study of EP4 Antagonist AAT-007 in Oncology in the People's Republic of China
September 2019 Concludes license agreement with Oxford Cannabinoid Technologies for AAT-730 in worldwide except Japan
October 2019 RMX (Haihe) initiates Clinical Study of COX-2 Inhibitor AAT-076 for Pain Therapy in the People's Republic of China
October 2020 Issues new shares to third parties (capital 237,091,500 yen)
November 2020 Issues new shares to third parties (capital 267,081,850 yen)
March 2021 Issues new shares to third parties (capital 282,091,000 yen)

PAGE TOP

Menu